Cairo, January 3, 2026 — A surprisingly simple strategy—low-dose, continuous capecitabine—is showing remarkable, decade-long benefits for women with early-stage triple-negative breast cancer (TNBC), according to an update from a pivotal Chinese clinical trial. Could this be a game-changer for a notoriously difficult-to-treat cancer?
Long-Term Capecitabine: A Decade of Durable Survival in TNBC
Table of Contents
A 10-year follow-up of the SYSUCC-001 trial reveals that metronomic capecitabine offers sustained disease-free survival, particularly in patients with high levels of the FOXC1 biomarker.
- The SYSUCC-001 trial demonstrated a significant improvement in disease-free survival at 10 years with low-dose capecitabine.
- The FOXC1 biomarker appears to predict which patients will benefit most from this approach.
- This strategy offers a potentially less toxic and more accessible treatment option, especially where immunotherapy isn’t readily available.
- Researchers suggest this highlights the power of repurposing existing drugs for targeted precision oncology.
What if a readily available, affordable oral chemotherapy could dramatically improve long-term outcomes in triple-negative breast cancer? That’s the compelling message emerging from the 10-year follow-up of the phase III SYSUCC-001 trial, recently reported in The Lancet Oncology.
The SYSUCC-001 Trial: A Closer Look
The trial enrolled women diagnosed with early-stage TNBC who had undergone surgery and standard adjuvant therapy. Participants were randomly assigned to receive metronomic capecitabine—650 mg/m² twice daily for one year—or observation. Researchers followed the patients for a median of 116 months (approximately 10 years).
A: The trial revealed a statistically significant improvement in disease-free survival (DFS) with metronomic capecitabine, with 78.1% of patients remaining disease-free compared to 66.6% in the observation group (HR 0.61, P = 0.007).
The results are striking. At 10 years, disease-free survival (DFS) reached 78.1% in the capecitabine group versus 66.6% in the observation group (hazard ratio [HR] 0.61, P = 0.007). Distant DFS mirrored this benefit (78.1% vs. 66.5%, HR 0.61, P = 0.0075), as did locoregional relapse-free survival (81.6% vs. 69.9%, HR 0.60, P = 0.011). Overall survival showed a numerical improvement (82.4% vs. 73.7%) and a trend toward statistical significance.
FOXC1: A Potential Biomarker for Patient Selection
Interestingly, the study also identified a potential biomarker to help predict who might benefit most from this treatment. Patients with tumors expressing high levels of FOXC1 experienced a particularly pronounced survival advantage.
For those with FOXC1-high tumors, the benefit was clear. In contrast, patients with FOXC1-low tumors saw a more modest effect, suggesting a potential pathway toward biologically driven treatment de-escalation or intensification.
One patient’s story illustrates the potential impact. Four years ago, a woman in her early 40s, diagnosed with early TNBC, continued on metronomic capecitabine after completing standard adjuvant chemotherapy due to high-risk features and excellent tolerance. Over four years, she maintained a stable quality of life, experienced minimal toxicity, and remained disease-free—a real-world outcome now supported by rigorous trial data.
Clinical Implications
These findings have several important implications for clinical practice. Metronomic capecitabine isn’t just a 5-year DFS story; it’s a 10-year survival story. FOXC1 testing may help identify patients who are most likely to benefit. And this low-dose, continuous therapy approach is powerful, practical, and patient-friendly.
This approach warrants consideration in high-risk early TNBC, particularly in settings where access to immunotherapy is limited. As one physician noted, precision oncology isn’t always about discovering new drugs—sometimes, it’s about using existing drugs in novel ways for the right patient.
What are your thoughts on this promising approach to TNBC treatment? Share your perspective in the comments below.
